Gregory Norden
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| PRAX | ▲ Buy | Grant | 1,371 | $0 | 6/10/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,045 | $161K | 5/14/2026 | View on chart |
| ZTS | ▼ Sell | Gift | 1,213 | $0 | 3/9/2026 | View on chart |
| ZTS | ▼ Sell | Other | 406 | $52K | 2/19/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,619 | — | 2/19/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 33,500 | $1.2M | 8/11/2025 | View on chart |
| RPRX | ▼ Sell | Other | 144,660 | $0 | 8/8/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 7,614 | $0 | 5/13/2025 | View on chart |
| ZTS | ▼ Sell | Gift | 1,843 | $0 | 2/14/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,225 | — | 2/8/2025 | View on chart |
| ZTS | ▼ Sell | Other | 308 | $53K | 2/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,236 | — | 2/6/2025 | View on chart |
| ZTS | ▼ Sell | Other | 310 | $54K | 2/6/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 9,293 | $0 | 6/7/2024 | View on chart |
| ZTS | ▼ Sell | Gift | 2,214 | $0 | 2/21/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,463 | — | 2/10/2024 | View on chart |
| ZTS | ▼ Sell | Other | 367 | $72K | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,493 | — | 2/8/2024 | View on chart |
| ZTS | ▼ Sell | Other | 375 | $73K | 2/8/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 7,747 | $0 | 6/23/2023 | View on chart |
| ZTS | ▼ Sell | Gift | 5,318 | $0 | 5/5/2023 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,626 | — | 2/11/2023 | View on chart |
| ZTS | ▼ Sell | Other | 408 | $65K | 2/11/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 6,328 | $0 | 6/24/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 2,673 | — | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Other | 671 | $133K | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Open Market | 4,500 | $972K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.